Drugs / AMG 811
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01510951 | Aug 2011 → Oct 2012 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00818948 | Mar 2009 → Jun 2014 | nephritis, systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02291588 | Dec 2007 → Mar 2010 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01164917 Comparator | Aug 2010 → Sep 2012 | discoid lupus erythematosus, systemic lupus erythematosus | Amgen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 811 | “This study sought to evaluate a single dose of AMG 811, an anti-IFNγ antibody, in patients with DLE.” PMID 28118537 ↗ Mar 2017 |
| Action | Inhibit | “anti-interferon (IFN)-γ monoclonal antibody AMG 811” PMID 29018537 ↗ Sep 2017 |
| Modality | Monoclonal antibody | “anti-interferon (IFN)-γ monoclonal antibody AMG 811” PMID 29018537 ↗ Sep 2017 |
| Route | Subcutaneous | “subjects without LN were randomised to subcutaneous AMG 811 (6, 20 or 60 mg) or placebo” PMID 29018537 ↗ Sep 2017 |
| Target | IFNG | “anti-interferon (IFN)-γ monoclonal antibody AMG 811” PMID 29018537 ↗ Sep 2017 |